Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study
- PMID:27210031
- DOI: 10.1016/S2215-0366(16)30065-7
Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study
Abstract
Background: Psilocybin is a serotonin receptor agonist that occurs naturally in some mushroom species. Recent studies have assessed the therapeutic potential of psilocybin for various conditions, including end-of-life anxiety, obsessive-compulsive disorder, and smoking and alcohol dependence, with promising preliminary results. Here, we aimed to investigate the feasibility, safety, and efficacy of psilocybin in patients with unipolar treatment-resistant depression.
Methods: In this open-label feasibility trial, 12 patients (six men, six women) with moderate-to-severe, unipolar, treatment-resistant major depression received two oral doses of psilocybin (10 mg and 25 mg, 7 days apart) in a supportive setting. There was no control group. Psychological support was provided before, during, and after each session. The primary outcome measure for feasibility was patient-reported intensity of psilocybin's effects. Patients were monitored for adverse reactions during the dosing sessions and subsequent clinic and remote follow-up. Depressive symptoms were assessed with standard assessments from 1 week to 3 months after treatment, with the 16-item Quick Inventory of Depressive Symptoms (QIDS) serving as the primary efficacy outcome. This trial is registered with ISRCTN, number ISRCTN14426797.
Findings: Psilocybin's acute psychedelic effects typically became detectable 30-60 min after dosing, peaked 2-3 h after dosing, and subsided to negligible levels at least 6 h after dosing. Mean self-rated intensity (on a 0-1 scale) was 0·51 (SD 0·36) for the low-dose session and 0·75 (SD 0·27) for the high-dose session. Psilocybin was well tolerated by all of the patients, and no serious or unexpected adverse events occurred. The adverse reactions we noted were transient anxiety during drug onset (all patients), transient confusion or thought disorder (nine patients), mild and transient nausea (four patients), and transient headache (four patients). Relative to baseline, depressive symptoms were markedly reduced 1 week (mean QIDS difference -11·8, 95% CI -9·15 to -14·35, p=0·002, Hedges' g=3·1) and 3 months (-9·2, 95% CI -5·69 to -12·71, p=0·003, Hedges' g=2) after high-dose treatment. Marked and sustained improvements in anxiety and anhedonia were also noted.
Interpretation: This study provides preliminary support for the safety and efficacy of psilocybin for treatment-resistant depression and motivates further trials, with more rigorous designs, to better examine the therapeutic potential of this approach.
Funding: Medical Research Council.
Copyright © 2016 Carhart-Harris et al. Open Access article distributed under the terms of CC BY. Published by Elsevier Ltd.. All rights reserved.
Comment in
- Altered states: psilocybin for treatment-resistant depression.Cowen P.Cowen P.Lancet Psychiatry. 2016 Jul;3(7):592-3. doi: 10.1016/S2215-0366(16)30087-6. Epub 2016 May 17.Lancet Psychiatry. 2016.PMID:27210032No abstract available.
- Psilocybin: panacea or placebo?Hendrie C, Pickles A.Hendrie C, et al.Lancet Psychiatry. 2016 Sep;3(9):805-6. doi: 10.1016/S2215-0366(16)30103-1.Lancet Psychiatry. 2016.PMID:27568263No abstract available.
- Question-based Drug Development for psilocybin.Dijkstra FM, Jacobs GE, Cohen AF.Dijkstra FM, et al.Lancet Psychiatry. 2016 Sep;3(9):806-7. doi: 10.1016/S2215-0366(16)30214-0.Lancet Psychiatry. 2016.PMID:27568265No abstract available.
Similar articles
- Psilocybin with psychological support for treatment-resistant depression: six-month follow-up.Carhart-Harris RL, Bolstridge M, Day CMJ, Rucker J, Watts R, Erritzoe DE, Kaelen M, Giribaldi B, Bloomfield M, Pilling S, Rickard JA, Forbes B, Feilding A, Taylor D, Curran HV, Nutt DJ.Carhart-Harris RL, et al.Psychopharmacology (Berl). 2018 Feb;235(2):399-408. doi: 10.1007/s00213-017-4771-x. Epub 2017 Nov 8.Psychopharmacology (Berl). 2018.PMID:29119217Free PMC article.Clinical Trial.
- Single-Dose Synthetic Psilocybin With Psychotherapy for Treatment-Resistant Bipolar Type II Major Depressive Episodes: A Nonrandomized Open-Label Trial.Aaronson ST, van der Vaart A, Miller T, LaPratt J, Swartz K, Shoultz A, Lauterbach M, Sackeim HA, Suppes T.Aaronson ST, et al.JAMA Psychiatry. 2024 Jun 1;81(6):555-562. doi: 10.1001/jamapsychiatry.2023.4685.JAMA Psychiatry. 2024.PMID:38055270Free PMC article.Clinical Trial.
- The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression.Goodwin GM, Aaronson ST, Alvarez O, Carhart-Harris R, Chai-Rees J, Croal M, DeBattista C, Dunlop BW, Feifel D, Hellerstein DJ, Husain MI, Kelly JR, Kirlic N, Licht RW, Marwood L, Meyer TD, Mistry S, Nowakowska A, Páleníček T, Repantis D, Schoevers RA, Simmons H, Somers M, Teoh E, Tsai J, Wahba M, Williams S, Young AH, Young MB, Zisook S, Malievskaia E.Goodwin GM, et al.J Affect Disord. 2025 Mar 1;372:523-532. doi: 10.1016/j.jad.2024.12.061. Epub 2024 Dec 18.J Affect Disord. 2025.PMID:39706482
- Psychedelic-assisted therapy for treating anxiety, depression, and existential distress in people with life-threatening diseases.Schipper S, Nigam K, Schmid Y, Piechotta V, Ljuslin M, Beaussant Y, Schwarzer G, Boehlke C.Schipper S, et al.Cochrane Database Syst Rev. 2024 Sep 12;9(9):CD015383. doi: 10.1002/14651858.CD015383.pub2.Cochrane Database Syst Rev. 2024.PMID:39260823
- Efficacy and safety of psilocybin in the treatment of Major Depressive Disorder (MDD): A dose-response network meta-analysis of randomized placebo-controlled clinical trials.Swieczkowski D, Kwaśny A, Pruc M, Gaca Z, Szarpak L, Cubała WJ.Swieczkowski D, et al.Psychiatry Res. 2025 Feb;344:116337. doi: 10.1016/j.psychres.2024.116337. Epub 2024 Dec 23.Psychiatry Res. 2025.PMID:39754904
Cited by
- Direct Phosphorylation of Psilocin Enables Optimized cGMP Kilogram-Scale Manufacture of Psilocybin.Kargbo RB, Sherwood A, Walker A, Cozzi NV, Dagger RE, Sable J, O'Hern K, Kaylo K, Patterson T, Tarpley G, Meisenheimer P.Kargbo RB, et al.ACS Omega. 2020 Jul 1;5(27):16959-16966. doi: 10.1021/acsomega.0c02387. eCollection 2020 Jul 14.ACS Omega. 2020.PMID:32685866Free PMC article.
- Post-Psychedelic Reductions in Experiential Avoidance Are Associated With Decreases in Depression Severity and Suicidal Ideation.Zeifman RJ, Wagner AC, Watts R, Kettner H, Mertens LJ, Carhart-Harris RL.Zeifman RJ, et al.Front Psychiatry. 2020 Aug 7;11:782. doi: 10.3389/fpsyt.2020.00782. eCollection 2020.Front Psychiatry. 2020.PMID:32903724Free PMC article.
- Patient perspectives and experiences with psilocybin treatment for treatment-resistant depression: a qualitative study.Breeksema JJ, Niemeijer A, Krediet E, Karsten T, Kamphuis J, Vermetten E, van den Brink W, Schoevers R.Breeksema JJ, et al.Sci Rep. 2024 Feb 5;14(1):2929. doi: 10.1038/s41598-024-53188-9.Sci Rep. 2024.PMID:38316896Free PMC article.Clinical Trial.
- Psychedelics and Consciousness: Expanding the Horizons of Mind and Therapy.Zhang M, Wang Y, Gao TM, Wang X.Zhang M, et al.Research (Wash D C). 2024 Oct 4;7:0495. doi: 10.34133/research.0495. eCollection 2024.Research (Wash D C). 2024.PMID:39371688Free PMC article.Review.
- Study protocol for "MDMA-assisted therapy as a treatment for major depressive disorder: A proof of principle study".Kvam TM, Goksøyr IW, Stewart LH, Repantis D, Røssberg JI, Andreassen OA.Kvam TM, et al.Front Psychiatry. 2022 Oct 26;13:954388. doi: 10.3389/fpsyt.2022.954388. eCollection 2022.Front Psychiatry. 2022.PMID:36386973Free PMC article.